[1] Casey BP, Glazer PM. Gene targeting via triple-helix formation[J]. Prog Nucleic Acid Res Mol Biol, 2001, 67(2):163-192.
[2] Temsamani J, Agrawal S. Antisense oligonucleotides as antiviral agents[J]. Adv Antiviral Drug Des, 1996, 10(1):21-39.
[3] Panyutin IG, Neumann RD. Sequence specific DNA breaks producd by triplex-directed decay of iodine-125[J]. Acta Oncol, 2000, 35(7):817-823.
[4] Cammilleri S, Perdereau B, Brixy F, et al. Imaging and biodistribution of 125I tyramine oligonucleotide in nude mice bearing human breast tumor. Preliminary report[J]. Bull Cancer Paris, 1996, 83(1):23-26.
[5] Sedelnikova OA, Panyutin IG, Thierry AR, et al. Radiotoxicity of iodine-125-labeled oligodeoxyribonucleotides in mammalian cells[J]. J Nucl Med, 1998, 39(8):1412-1418.
[6] Karamychev VN, Panyutin IG, Kim MK, et al. DNA cleavage by 111In-labeled oligodeoxyribonucleotides[J]. J Nucl Med, 2000, 41(6):1093-1101.
[7] Winnard PJ, Chang F, Rusckowski M, et al. Preparation and use of NHS MAG3 for technetium-99m labeling of DNA[J]. Nucl Med Biol, 1997, 24(5):425-432.
[8] Fujibayashi Y, Nakagawa K, Waki A, et al. Basic studies on the 111In labeled antisense oligonucleutide for tumor imaging[J]. Kaku Igaku, 1996, 33(2):115-122.
[9] Watanabe N, Sawai H, Endo K, et al. Labeling of phosphorothioate antisense oligonucleotides with yttrium-90[J]. Nucl Med Biol, 1999, 26(2):239-243.
[10] Fujibayashi Y, Yoshimi E, Waki A, et al. A novel 111In-la-beled antisense DNA probe with multi-chelating sites (MCSprobe) showing high specific radioactivity and labeling efficiency[J]. Nucl Med Biol, 1999, 26(1):17-21.
[11] Gonzalez Ferreiro M, Tillman L, Hardee G. Characterization of complexes of an antisense oligonucleotide with protamine and poly-L-lysine salts[J]. J Control Release, 2001, 73(2-3):381-390.
[12] Sugano M, Makino N, Sawada S, et al. Effect of antisense oligodeoxynucleotides against cholestryl estertansfer protein on the development of atherosclerosis in cholesterol-fed rabbits[J]. J Biol Chem, 1998, 273(9):5033-5036.
[13] Reddy JA, Low PS. Folate-mediated targeting of therapeutic and imaging agents to cancers[J]. Crit Rev Ther Carrier Syst, 1998, 15(6):587-627.
[14] Agrawal S. Antisense oligonucleotides:towards clinical trials[J]. Tibtech, 1996, 14(10):376-387.
[15] Hnatowich DJ, Winnard PJ, Virzi F, et al. Labeling deoxyribonucleic acid oligonucleotides with 99Tcm[J]. J Nucl Med, 1995, 36(12):2306-2314.
[16] Kairemo KJ, Tenhunen M, Jekunen AP. Dosimetry of radionuclide therapy using radiophosphonated autisense oligodeoxynucleotide phosphorothioates based on animal pharmacokinetic and tissue distribution data[J]. Antisense Nucleic Acid Drug Dev, 1996, 6(3):215-220.